SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Patent ExpiryMDMA-N-acylethanolaminesPositive

AI Analysis

Summary

SciSparc, NeuroThera, and Clearmind announced a collaboration advancing MDMA-N-acylethanolamines for PTSD treatment, with U.S. patent application publication expanding intellectual property and providing clinical development guidance for psychedelic drugs.

Outcome Details

U.S. publication of patent application covering MDMA-N-acylethanolamines combination

Importance:5/10

Sentiment:

0.60

MDMAPTSDPsychedelicIntellectual PropertyPatentCollaboration

Related Companies

$SPRC $CMND

Read the original article

Published by GlobeNewswire Pharma on August 24, 2026 12:51 PM

Read Original